Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML-001

In the phase 3 QUAZAR AML-001 trial (NCT01757535) of patients with acute myeloid leukaemia (AML) in remission following intensive chemotherapy (IC) and ineligible for haematopoietic stem cell transplant (HSCT), oral azacitidine (Oral-AZA) maintenance significantly prolonged overall survival (OS) ver...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	British journal of haematology 2024-03, Vol.204 (3), p.877-886
Hauptverfasser:	Ravandi, Farhad, Döhner, Hartmut, Wei, Andrew H, Montesinos, Pau, Pfeilstöcker, Michael, Papayannidis, Cristina, Lai, Yinzhi, Wang, Kefeng, See, Wendy L, de Menezes, Daniel Lopes, Petrlik, Erica, Prebet, Thomas, Roboz, Gail J
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute myeloid leukemia Chemotherapy Hematopoietic stem cells Leukemia Placebos Remission Stem cell transplantation
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!